May 1st-3rd, 2018

London, UK

2018 Speakers


Tuc Ahmad
Scientific Director, Diagnostic Development

Steve Anderson

Benoit Canolle
Director, Precision Medicine
Pierre Fabre

Carlos Cara
Head, Medical Immunology International Markets

Kaan Certel
Head of External Innovation, Oncology

Ruggero De Maria
Alliance Against Cancer

Claudia Dollins
Head, Global Regulatory Affairs, Biomarkers & Diagnostics
Merck KGaA

Jörg Engelbergs
Scientific Expert Biomedicines
Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines

Mark Fidock
Vice President & Head, Precision Medicine Laboratories

Sibylle Hess
Clinical Biomarker Expert, TMED, BCB

Colin Hill
SVP, Commercial Operations

Hugues Malonne
Director General, Post-Authorization

Mirella Marlow
Programme Director, Devices & Diagnostic Systems

Hugh Marston
Senior Research Fellow & Head, Translational Neuroscience
Eli Lilly

Hugh Marston is a senior research fellow leading the Translational Neuroscience Group at Lilly’s Erl Wood research site in Surrey supporting all of Lilly’s active neuroscience programmes. Erl Wood’s research focus covers novel approaches designed to modify neurodegeneration, chronic pain and effective neurosymptomatic intervention. Having originally trained as a psychopharmacologist at Cambridge he has now had nearly 30 years’ experience in various forms of drug discovery research. Most recently as head of pharmacology at IOMet Pharma (pka TPP GD) a virtual pharma company acquired by Merck in 2016.  Prior to that he has lead neuropharmacology teams at Merck, Schering-Plough and Organon working on projects principally in the psychiatry area from discovery through to launch.  As such he has had a long standing interest in transforming our ability to translate science to and from the clinic across the neuroscience disciplines. As part of his role at Lilly he is Project Leader of the IMI2 PRISM initiative an industry/academe EU funded consortium that is seeking to find translatable, quantitative biological phenotypes in CNS disorders.  He maintains an active interest in academic research through collaboration and an honorary professorship at the University of St Andrews with 70+ peer reviewed publications and five granted patents.

Shane McGann
Senior Manager, Regulatory Affairs
Agios Pharmaceuticals

Christopher Peters
Clinical Senior Lecturer, Consultant Upper GI & General Surgeon
Imperial College London

Christopher Peters went to medical school in Leeds and after completing basic surgical training moved to Cambridge to carry out a PhD with Professor Rebecca Fitzgerald. During his PhD he developed a four gene signature to predict outcome in oesophageal adenocarcinoma which was validated in 371 independent cases. He also set up the OCCAMS collaboration which went on to be selected to run the International Cancer Genome Consortium's Whole Genome sequencing project in oesophageal adenocarcinoma. OCCAMS has ongoing CRUK funding and has now recruited in excess of 3000 patients. After moving to London to complete his higher surgical training he was appointed as a Clinical Senior Lecturer and Consultant Upper GI surgeon at Imperial College London with a specialist interest in Biomarkers. His academic interest is molecular and clinical predictors of outcome in Oesophageal adenocarcinoma, and in particular developing ways of combining the two to improve stratification of patients. As the Biomarker lead for the NIHR London IVD Co-operative he also has a programme built around trying to better understand which Biomarkers are likely to achieve clinical adoption- aiming to bridge the gap between the millions spent on Biomarker discovery and validation and the handful that achieve clinical success.

Mark Roberts
Senior Director, Diagnostics Development

Dieter Schönwald
Global Technical Officer, IVD

Simon Shohet
Senior Director, Market Access & Pricing

Dominic Smethurst
Tusk Therapeutics

Andreas Stange
Vice President MHS, Global IVD

Kristin Stieler
Technical & Clinical Product Lead – Europe
Sysmex Inostics

Farhat Syed
Associate Director, Precision Medicine

Steen Thaarup
Business Development Manager, Pharma

Tom Turi
Vice President, Companion Diagnostics

Caoimhe Vallely-Gilroy
Director & Head, Clinical Trials Biosample Management
Merck KGaA

Steven Walker
Head of Internal Product Management
Almac Diagnostics

Dr Steven Walker heads the internal product management activities at Almac Diagnostics.  Specifically this includes the development of internal discovery of biomarker assays towards commercialisation as a diagnostic test delivered directly from Almac CLIA and CAP accredited laboratories, or as a companion diagnostic test for in partnership with Pharma / Biopharma. Steven studied at the University of Dundee, leading to a PhD before postgraduate work at the Beatson Cancer Research UK Institute in Glasgow. He joined Almac Diagnostics in 2005, initially as a Senior Scientist, then as Team Leader and then Research Manager before taking the role in Product Development. As part of his time with the research team, he was involved in the discovery and development of several of the internally discovered biomarker assays.

Alan Wookey
Scientific Advisor, Oncology and Companion Diagnostics
Q2 Solutions